AX 1505 - Axim Biotech

Drug Profile

AX 1505 - Axim Biotech

Alternative Names: AX-1505

Latest Information Update: 10 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axim Biotech
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Crohn's disease

Most Recent Events

  • 09 Nov 2016 Preclinical trials in Crohn's disease in USA (PO)
  • 09 Nov 2016 Axim Bitoech announces intention to submit NDA in 2020 (Axim Biotech pipeline, November 2016)
  • 09 Nov 2016 Axim Biotech plans a phase IIa trial for Crohn's disease in USA (Axim Biotech pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top